Commissariat a L'energie Atomique Et Aux Energies Alternatives

Centre National De La Recherche Scientifique

Commissariat a L'energie Atomique

Ipsen Pharma S.a.s.

Institut Gustave Roussy

The University of Texas System

Institut Curie

Le Centre National De Recherche Scientifique (Cnrs)

Centre National De La Recherche Scientifique-Cnrs

Jean-Christophe Cintrat

Daniel Gillet

Julien Barbier

Thomas Rudel

Jo-Ana Herweg

Annette Fischer

Roland Cherif-Cheikh

Eric Deutsch

Bernard Rousseau

Frederic Taran

Catherine Brenner

Marie-Thérèse Paternostre

Jean Luc Perfettini

Franck Artzner

Céline Valery

Romain Noel

Ludger Johannes

Eric Marechal

Stéphane Roux

Robert A Davey

Caroline Barette

Frédéric Taran

Melinda Ligeti

Fabrice Rebeille

Juliette Jouhet

Valérie Pons

Livia Tepshi

Robin Vinck

Audrey Couhert

Alain Pruvost

Melissa Conte

Lina-Juana Dolch

Coline Mei

Nicolas Fay

Christophe Tarabout

Dimitris Petroutsos

Denis Falconet

Maarten Ijsselstijn

Hajer Abdelkafi

Karen Hinsinger

Roland Chérif-cheikh

Roland Cherif-cheikh

The invention relates to a new family of compounds of the type 2,3-dihydroquinazolin-4(1H)-one and the use thereof as inhibitors of the toxic effects of intracellular-acting toxins, such as ricin, Shiga toxins or the cholera toxin, using retrograde transport to intoxicate the cells, or viruses or bacteria using retrograde and/or syntaxin 5-dependent transport to infect the cells, specifically viruses or bacteria entering into the cells by means of endocytosis, or intracellular parasites.

Dihydroquinazolinones exhibiting protective activity against intracellular-acting toxins, intracellular viruses and bacteria

The present invention is drawn to the use of Minaprine dihydrochloride and analogs thereof, for reducing tumor growth when administered to a patient suffering from cancer.

Use of minaprine to reduce tumor growth

The present invention is drawn to the use of the compounds highlighted in Tables 1 & 2 and analogs thereof, for enhancing IR-mediated cellular cannibalism in cancer cells. Said compounds are herein called 'enhancers of IR-mediated cellular cannibalism'. They can be used to enhance tumor immunogenicity and/or to induce a significant protective anticancer immune response in subjects that will receive or that have received a radiotherapy treatment. In other words, said compounds can be used to potentiate a radiotherapy treatment in a subject in need thereof. Said compounds are preferably chosen in the group consisting of: Mebhydroline 1,5-napthalene disulfonate salt, Flurbiprofen, Minaprine dihydrochloride, Myricetin, Digoxin, Digitoxin, Lanatoside, LOPA87, VP331, RN-1-026, SG6163F, VP450, and VP43.

Enhancers of cellular cannibalism for use to sensitize tumors to radiation therapy

The invention relates to a method for treating a Chlamidyales infection comprising the administration of a therapeutically effective amount of a compound of formula (I) to a subject in need thereof: Wherein R, R, Rand Ar are as defined in claim

Benzodiazepine derivatives for use in the treatment of Chlamydiales infections

The invention relates to a method for accumulating triacylglycerols in microalgae by inhibiting the sterol metabolism, by incubating the microalgae with an inhibitor of sterol metabolism. The invention also relates to a method for producing fatty acids, biofuels, pharmaceutical or cosmetic compositions, and also food supplements, comprising a triacylglycerols accumulation step in microalgae according to the invention. Finally, the invention concerns the use of an inhibitor of sterol metabolism to accumulate triglycerides in microorganisms, and preferably microalgae.

Inhibitors of sterol metabolism for their use to accumulate triglycerides in microalgae, and methods thereof

The present invention relates to a method for treating a Chlamydiales infection comprising the administration of a therapeutically effective amount of a compound of formula (I) to a subject in need thereof:W-L-NH-L-Ar&#x2003;&#x2003; (I)Wherein W, L1, L2 and Ar are as defined in claim

Adamantane or pinene derivatives for use in the treatment of chlamydiales infections

Use of 2,3-dihydroquinazolin-4(1H)-one cyclic derivatives of formula (I) for the treatment of infection with viruses entering cells by endocytosis, especially filovirus such as Ebolavirus. 

2,3-dihydroquinazolin-4(1H)-one derivatives for use in the treatment of viral infections

The present invention relates to a method for treating a Chlamydiae infection comprising the administration of a therapeutically effective amount of a compound of formula (I) to a subject in need thereof: Wherein, R1, R2, R3, R4 and p are as defined in claim

Quinazolinone derivatives for use in the treatment of chlamydiales infections

The present invention concerns a new family of 2,3-dihydroquinazolin-4(1H)-one compounds of general formula (I), and the use thereof as inhibitors of the toxic effects of toxins with intracellular activity, such as ricin or Shiga toxin, for example, using retrograde transport to intoxicate cells.

Compounds having a protective activity against toxins with intracellular activity

The present invention relates to novel octapeptide compounds of general formula (I): H-2-Nal-cyclo(Cys-Tyr-AA-Lys-Val-Cys)-Thr-NH. Since these products have a good affinity for certain somatostatin receptor subtypes, they are particularly advantageous for treating pathological states or diseases in which one (or more) somatostatin receptor(s) is (are) involved. These compounds furthermore have physiochemical properties that make it possible to envisage them in diverse solutions for the formulation of medicaments, for example as a pharmaceutically acceptable carrier. The invention also relates to pharmaceutical compositions containing said products and to the use thereof for the preparation of a medicament.

Octapeptide compounds derived from somatostatin and the therapeutic use thereof

The present invention relates to novel octapeptide compounds of general formula (I),R-AA-cyclo(AA-Tyr-D-Trp-AA-Val-Cys)-Thr-NH&#x2003;&#x2003;(I)As these products have a good affinity for certain sub-types of somatostatin receptors, they are particularly useful for treating the pathological states or diseases in which one (or more) of the somatostatin receptors is (are) involved. The invention also relates to pharmaceutical compositions containing said products and their use for the preparation of a medicament.

Octapeptide compounds and therapeutic use thereof

Growing community of inventors

Igny, France

Jean-Christophe Cintrat